Is Cardax, Inc. (CDXI) a Buy, Sell, or Hold?
OTC : CDXI
Cardax, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 1
- Average Volume
- 2
- Market Capitalization
- $80
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.11
Company Overview
OTC
David G. Watumull
Biotechnology
Healthcare
CDXI
10
US
USD
Liquidity Metrics
-0.47
0.11
0.01
0.00
0.00
Sales & Valuation
$538.95K
0.00
0.00
0.00
-2.43
Profitability
-$6.79
-$5.06M
-938.04%
-938.04%
58.12%
-354.73%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-91.51
3/9
-$11.36M
$1.38M
$12.73M
-$3.07M
Key Metrics (TTM)
$4.76M
8.84
-1.81
0.11
58.12%
57.33%
-6789971.19%
-2257745.00%
-475 days
Company Executives
| Name | Title |
|---|---|
| David Watumull | Chairman & Chief Executive Officer |
| Gilbert Shin | Vice President of Retail Sales & Marketing |
Poll Results
No votes yet today — be the first to share your view!
About Cardax, Inc. (OTC:CDXI) Stock
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currentl ... y under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.
Frequently Asked Questions
-
What is the current Cardax, Inc. (CDXI) stock price?
-
Cardax, Inc.(OTC:CDXI) stock price is $0.0001 in the last trading session. During the trading session, CDXI stock reached the peak price of $0.004 while $0.000001 was the lowest point it dropped to. The percentage change in CDXI stock occurred in the recent session was 0.0% while the dollar amount for the price change in CDXI stock was $0.
-
CDXI's industry and sector of operation?
-
The OTC listed CDXI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CDXI?
-
David Watumull | Chairman & Chief Executive Officer
Gilbert Shin | Vice President of Retail Sales & Marketing
|
|
| -
How many employees does CDXI have?
-
Number of CDXI employees currently stands at 10. CDXI operates from 2800 Woodlawn Drive, Honolulu, HI 96822, US.
-
Link for CDXI official website?
-
Official Website of CDXI is: https://www.cardaxpharma.com
-
How do I contact CDXI?
-
CDXI could be contacted at phone #808 457 1400 and can also be accessed through its website. CDXI operates from 2800 Woodlawn Drive, Honolulu, HI 96822, US.
-
How many shares of CDXI are traded daily?
-
The average number of CDXI shares traded daily for last 3 months was 2.
-
What is the market cap of CDXI currently?
-
The market value of CDXI currently stands at $80 with its latest stock price at $0.0001